Dow Jones
34.053,94 -39,02 (-0,11%) Nasdaq
12.200,82 +384,50 (+3,25%) Nikkei 225
27.478,56 +76,51 (+0,28%) EUR/USD
1,0902 -0,0010 (-0,09%) BTC-EUR
21.635,67 -293,67 (-1,34%) CMC Crypto 200
541,21 -4,11 (-0,75%)
Editas Medicine, Inc. (EDIT)
Dopo ore:
- GlobeNewswire
Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies
Shoreline to obtain an exclusive license to SLEEK knock-in technology for iPSC-derived NK cells, an exclusive license to SLEEK for iPSC-derived macrophages in oncology and a non-exclusive license for AsCas12a Shoreline to acquire Editas Medicine’s iNK cell franchise, including EDIT-202 and certain related manufacturing technologies Economics to Editas Medicine to include upfront payment, and development and commercial milestone and royalty payments CAMBRIDGE, Mass. and SAN DIEGO, Jan. 19, 2023 (
- GlobeNewswire
Editas Medicine Announces Strategic Updates and Portfolio Reprioritization
Strategic reprioritization of portfolio to focus on hemoglobinopathies and in vivo gene editing Discontinuing internal investments in inherited retinal diseases and in preclinical wholly owned iNK programs Mark S. Shearman, Ph.D., Chief Scientific Officer to step down, departing March 31 Reprioritization reduces workforce by approximately 20%, expected to extend cash runway into 2025 Company to present at the 41st Annual J.P. Morgan Healthcare Conference January 10 CAMBRIDGE, Mass., Jan. 09, 202
- GlobeNewswire
Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced that the Company’s President and CEO Gilmore O’Neill, M.B., M.M.Sc., will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, 4:30 p.m. PT / 7:30 p.m. ET in San Francisco, CA. A live webcast of the presentation will be available on the “Investors” section of the Editas Medicine website at www.editasmedicine.com.
